Manufacturer Supply High Quality CAS 1208319-27-0 Oclacitinib Maleate

• CAS No.: 1208319-27-0
• Formula: C19h27n5o6s
• EINECS: 204-726-0
• Type: Synthesis Material Intermediates
• Appearance: White Powder
• Quality: Industrial
• Model NO.: TY-02ALI
• Colour: White
• Package: Foil Bag
• Place: China
• Assay: 99%
• Shelf: 2 Years
• Transport Package: 25kg/Drum 5g, 100g, 500g, 1kg, 10kg, 100kg, 200kg
• Specification: 25kg/drum
• Trademark: tongyon
• Origin: China
• Production Capacity: 5000kg/Month

Product Description

 

Product name	Oclacitinib Maleate
CAS	1208319-27-0
Appearance	white powder
Assay	99%
Storage	Cool and Protect from light

Oclacitinib Maleate(PF-03394197)
Product Name Oclacitinib Maleate(PF-03394197)

CAS 1208319-27-0

MF C19H27N5O6S

MW 453.51

EINECS

MOL File1208319-27-0.mol


Usage And Synthesis
Description

APOQUEL (oclacitinib maleate) was the first selective Janus kinase (JAK) inhibitor to be developed for dogs. It was recently approved for the control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age. In recent years, there has been a significant evolution in understanding regarding the pathophysiology of allergic and atopic diseases. The molecular mechanisms involved in stimulating the itch response have been elaborated (Marsella et al., 2012), and it is now understood that cytokines play a key role in initiating the neuronal itch stimulation which triggers pruritic behavior (scratching, rubbing, chewing, etc.) in dogs. This leads to the establishment of a vicious cycle of itch that exacerbates skin lesions and amplifies defects in the skin barrier function in clinically affected dogs. This progress provided the opportunity to develop new treatments (Marsella et al., 2012). Specifically, Janus kinases play a central role in cytokine signaling and are involved in signal transduction of many pro-inflammatory, pro-allergic, and pruritogenic cytokines including IL-2, IL-4, IL-6, IL-13, and IL-31 that are implicated in allergic conditions (Ong & Leung, 2006; Carmi-Levy et al., 2011).

Uses

Oclacitinib is labeled to treat atopic dermatitis and itchiness (pruritus) caused by allergies in dogs, though it has also been used to reduce the itchiness and dermatitis caused by flea infestations. It is considered to be highly effective in dogs, and has been established as safe for at least short-term use. Its efficacy equals that of prednisolonee at first, though oclacitinib has been found to be more effective in the short term in terms of itchiness and dermatitis, long term safety is unknown. It has been found to have a faster onset and cause less gastrointestinal issues than cyclosporine. While safe in the short term, oclacitinib's long-term safety is unknown. While some say it is best only for acute flares of itchiness, others claim that it is also useful in chronic atopic dermatitis.

GuangZhou TongYi biochemistry technology Co., Ltd is a company specializing in active pharmaceutical ingredient
(API), biology, plant extracts, chemical raw materials, fine chemicals, pharmaceutical intermediates, cosmetics raw
material. Our company has always adhered to the company philosophy of integrity, professionalism, quality first, and
customer service. With the efforts of all the company's employees, it has established long-term
and stable cooperative relations with many domestic and foreign customers, and won the unanimous trust of domestic
and foreign customers. With good comments, our company have made great progress.

Our company takes pioneering and innovative, high-quality and efficient as the code of conduct, and strives to provide
customers with efficient services,
high-quality products, and reasonable prices. We have established a customer demand-oriented, flexible, diverse and customizable service according to the different needs of different customers. Mode, and ultimately achieve the goal of
win-win.

Our company focuses on the future and the world, and will continue to devote itself to technological progress and the
development of new products in the future, hoping to work hand in hand with new and old friends at home and abroad
to create a better future.